BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

559 related articles for article (PubMed ID: 17326150)

  • 1. Lactulose improves cognitive functions and health-related quality of life in patients with cirrhosis who have minimal hepatic encephalopathy.
    Prasad S; Dhiman RK; Duseja A; Chawla YK; Sharma A; Agarwal R
    Hepatology; 2007 Mar; 45(3):549-59. PubMed ID: 17326150
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A randomized controlled trial comparing lactulose, probiotics, and L-ornithine L-aspartate in treatment of minimal hepatic encephalopathy.
    Mittal VV; Sharma BC; Sharma P; Sarin SK
    Eur J Gastroenterol Hepatol; 2011 Aug; 23(8):725-32. PubMed ID: 21646910
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Primary prophylaxis of overt hepatic encephalopathy in patients with cirrhosis: an open labeled randomized controlled trial of lactulose versus no lactulose.
    Sharma P; Sharma BC; Agrawal A; Sarin SK
    J Gastroenterol Hepatol; 2012 Aug; 27(8):1329-35. PubMed ID: 22606978
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rifaximin vs. lactulose in treatment of minimal hepatic encephalopathy.
    Sidhu SS; Goyal O; Parker RA; Kishore H; Sood A
    Liver Int; 2016 Mar; 36(3):378-85. PubMed ID: 26201713
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Secondary prophylaxis of hepatic encephalopathy in cirrhosis: an open-label, randomized controlled trial of lactulose, probiotics, and no therapy.
    Agrawal A; Sharma BC; Sharma P; Sarin SK
    Am J Gastroenterol; 2012 Jul; 107(7):1043-50. PubMed ID: 22710579
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An open-label randomized controlled trial of lactulose and probiotics in the treatment of minimal hepatic encephalopathy.
    Sharma P; Sharma BC; Puri V; Sarin SK
    Eur J Gastroenterol Hepatol; 2008 Jun; 20(6):506-11. PubMed ID: 18467909
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Critical flicker frequency for diagnosis and assessment of recovery from minimal hepatic encephalopathy in patients with cirrhosis.
    Sharma P; Sharma BC; Sarin SK
    Hepatobiliary Pancreat Dis Int; 2010 Feb; 9(1):27-32. PubMed ID: 20133225
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predictors of nonresponse to lactulose for minimal hepatic encephalopathy in patients with cirrhosis.
    Sharma P; Sharma BC; Sarin SK
    Liver Int; 2009 Oct; 29(9):1365-71. PubMed ID: 19555401
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Minimal hepatic encephalopathy.
    Sharma P
    J Assoc Physicians India; 2009 Nov; 57():760-3. PubMed ID: 20329443
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rifaximin improves psychometric performance and health-related quality of life in patients with minimal hepatic encephalopathy (the RIME Trial).
    Sidhu SS; Goyal O; Mishra BP; Sood A; Chhina RS; Soni RK
    Am J Gastroenterol; 2011 Feb; 106(2):307-16. PubMed ID: 21157444
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sleep disturbances in patients of liver cirrhosis with minimal hepatic encephalopathy before and after lactulose therapy.
    Singh J; Sharma BC; Puri V; Sachdeva S; Srivastava S
    Metab Brain Dis; 2017 Apr; 32(2):595-605. PubMed ID: 28070704
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum endotoxin, inflammatory mediators, and magnetic resonance spectroscopy before and after treatment in patients with minimal hepatic encephalopathy.
    Jain L; Sharma BC; Srivastava S; Puri SK; Sharma P; Sarin S
    J Gastroenterol Hepatol; 2013 Jul; 28(7):1187-93. PubMed ID: 23425082
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical efficacy and safety of lactulose for minimal hepatic encephalopathy: a meta-analysis.
    Luo M; Li L; Lu CZ; Cao WK
    Eur J Gastroenterol Hepatol; 2011 Nov; 23(12):1250-7. PubMed ID: 21971378
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Secondary prophylaxis of hepatic encephalopathy: an open-label randomized controlled trial of lactulose versus placebo.
    Sharma BC; Sharma P; Agrawal A; Sarin SK
    Gastroenterology; 2009 Sep; 137(3):885-91, 891.e1. PubMed ID: 19501587
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Can Lactobacillus acidophilus improve minimal hepatic encephalopathy? A neurometabolite study using magnetic resonance spectroscopy.
    Ziada DH; Soliman HH; El Yamany SA; Hamisa MF; Hasan AM
    Arab J Gastroenterol; 2013 Sep; 14(3):116-22. PubMed ID: 24206740
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Effects of lactulose treatment on the course of subclinical hepatic encephalopathy].
    Zeng Z; Li YY
    Zhonghua Yi Xue Za Zhi; 2003 Jul; 83(13):1126-9. PubMed ID: 12921628
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lactulose improves cognition, quality of life, and gut microbiota in minimal hepatic encephalopathy: A multicenter, randomized controlled trial.
    Wang JY; Bajaj JS; Wang JB; Shang J; Zhou XM; Guo XL; Zhu X; Meng LN; Jiang HX; Mi YQ; Xu JM; Yang JH; Wang BS; Zhang NP
    J Dig Dis; 2019 Oct; 20(10):547-556. PubMed ID: 31448533
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Spectral electroencephalogram in liver cirrhosis with minimal hepatic encephalopathy before and after lactulose therapy.
    Singh J; Sharma BC; Maharshi S; Puri V; Srivastava S
    J Gastroenterol Hepatol; 2016 Jun; 31(6):1203-9. PubMed ID: 26716736
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predictors of nonresponse to lactulose in patients with cirrhosis and hepatic encephalopathy.
    Sharma P; Sharma BC; Sarin SK
    Eur J Gastroenterol Hepatol; 2010 May; 22(5):526-31. PubMed ID: 20009938
    [TBL] [Abstract][Full Text] [Related]  

  • 20. RiMINI - the influence of rifaximin on minimal hepatic encephalopathy (MHE) and on the intestinal microbiome in patients with liver cirrhosis: study protocol for a randomized controlled trial.
    Schulz C; Schütte K; Kropf S; Schmitt FC; Vasapolli R; Kliegis LM; Riegger A; Malfertheiner P
    Trials; 2016 Feb; 17(1):111. PubMed ID: 26926775
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.